source
- Pfizer reports flat Q3 revenue as non-COVID sales rise 7% and acquired products grow 32%Pfizer posted third‑quarter revenue of $16.6 billion, essentially unchanged from $16.7 billion a year earlier. The flat top line reflects declines in its legacy Prevnar vaccine and COVID‑related pr…
- Pfizer drops phase 2 pulmonary arterial hypertension candidate amid pipeline cutPfizer has discontinued its phase 2 pulmonary arterial hypertension (PAH) program, PF-07868489, citing business reasons rather than safety or efficacy concerns. The drug, which targets BMP9 inhibi…